Information Technology · Services-Business Services, NEC

OPRX OptimizeRx Corp SEC Filings & Insider Trading Activity 2026

company
CIK 1448431149 filings
Russell 2000

OPRX at a glance

OptimizeRx Corp (OPRX, SEC CIK 1448431) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), OptimizeRx Corp (OPRX) reported revenue of $109.4 million (up 18.8% from FY2024) and net income of $5.1 million. Diluted EPS was $0.27.
  • As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding OptimizeRx Corp (OPRX) shares worth $23.2 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$109.4M
+18.8% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
19 funds
$23.2M · −3 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $21,615, down 17% YoY from $26,067, reflecting managed-service declines and measured customer spending
  • Operating margin 12.4% vs 7.9% YoY, with net income $1,195 vs $779
  • Cost of revenue margin 25% vs 33%, driven by exiting low-margin managed services
  • Operating cash flow $12,880 vs $11,627; cash $22,325 and undrawn revolver $10,000
  • Outlook: sufficient liquidity for 12 months, with headwinds from tariffs, macroeconomic uncertainty and customer budget scrutiny

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward business risks could materially affect operations and financial condition
  • Additional unidentified or currently immaterial risks could adversely affect operating results

AI summary of the OPRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced November 11, 2026
  • Updated 2026 revenue guidance, signaling revised management expectations

Item EX-99.2: Item EX-99.2

  • Q3 revenue $21.6M, down 17% YoY, while Adjusted EBITDA rose to $6.3M from $5.1M
  • Adjusted EBITDA margin approximately 29%, up more than 900 basis points, signaling substantial operating leverage despite weaker sales

Item EX-99.1: Item EX-99.1

  • Q3 revenue fell 17% to $21.6 million, signaling continued weakness in in-year pharmaceutical contract demand
  • Adjusted EBITDA rose to $6.3 million from $5.1 million, with margin expansion offsetting lower revenue through product mix and cost controls
Filed Aug 12, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Andy D’Silva succeeds Ed Stelmakh as CFO effective January 1, 2027
  • Heather Favazza becomes Chief Accounting Officer on January 1, 2027 after eight years as Corporate Controller

Item 7.01: Regulation FD Disclosure

  • CFO & Strategy Officer Stelmakh departing effective December 31, 2026
  • D’Silva appointed Chief Financial Officer effective January 1, 2027

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CFO Edward Stelmakh departs December 31, 2026 after 12 months of advisory service, creating a planned finance leadership transition
  • Successor Andrew D’Silva brings internal continuity as CFO from January 1, 2027, with prior finance strategy and investor relations experience

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results announced for quarter ended June 30, 2026
  • Investor-relevant financial figures and management commentary contained in Exhibit 99.1
Filed Jun 12, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Shareholders approved 1,000,000 additional shares for equity awards under the 2021 Equity Incentive Plan
  • Total shares available increased to 5,450,000, expanding potential employee and executive compensation capacity

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All seven director nominees elected, with votes for ranging from 8,092,151 to 12,160,558
  • Executive compensation approved on an advisory basis, with 11,660,549 votes in favor

AI summaries of OPRX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OPRX

Don't miss the next OPRX filing

  • Alerts as it files. A push when OPRX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OPRX, by share count.
  • Ask anything. An AI agent that reads every OPRX filing and answers with sources.

OPRX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
D'Silva Andrew J.FOct 1, 2026$8.39
D'Silva Andrew J.FSep 1, 2026$7.86
Odence-Ford MarionFAug 21, 2026$7.71
Stelmakh EdwardFAug 21, 2026$7.71
Merrell Brendan W.FAug 21, 2026$7.71
Silvestro Stephen LFAug 21, 2026$7.71
D'Silva Andrew J.FAug 21, 2026$7.71
D'Silva Andrew J.AAug 20, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$92.1M$109.4M
Gross Profit-$59.4M$73.6M
Operating Income--$13.7M$11.7M
Net Income--$20.1M$5.1M
Gross Margin-64.5%67.3%
Op. Margin--14.9%10.7%
Net Margin--21.8%4.7%
Balance Sheet
Total Assets$183.4M$171.2M$176.9M
Equity$126.6M$117.0M$128.3M
ROE--17.2%4.0%
Per Share
EPS-$-1.10$0.27
Cash Flow
Operating CF-$4.9M$18.7M
CapEx-$112K$58K

Source: XBRL data in OptimizeRx Corp (OPRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OPRX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OPRX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202619$23.2M
Q2 202622$20.2M
Q1 202624$30.6M
Q4 202524$53.6M
Q3 202526$100.8M
Q2 202521$63.8M
Q1 202518$28.6M
Q4 202410$11.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 164 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OPRX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 13, 2026Analysis-
10-QNov 13, 2026Analysis
4Oct 2, 2026--
4Sep 2, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
SC 13GAug 14, 2026-
10-QAug 13, 2026Analysis
8-KAug 12, 2026Analysis-
SC 13GJul 22, 2026-
8-KJun 12, 2026Analysis-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-

Related Information Technology companies

All Information Technology →

OPRX SEC filings: frequently asked questions

Which institutions hold OPRX stock?

As of September 30, 2026, the largest OptimizeRx Corp (OPRX) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($5.8 million), Dimensional Fund Advisors ($3.7 million), BlackRock ($3.6 million), AQR Capital Management ($1.9 million), Morgan Stanley ($1.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was OPRX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), OptimizeRx Corp (OPRX) reported revenue of $109.4 million (up 18.8% from FY2024) and net income of $5.1 million. Diluted EPS was $0.27. The figures come from the XBRL data in the 10-K.

What did OPRX report in its latest 8-K?

OptimizeRx Corp (OPRX) filed an 8-K on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results for quarter ended September 30, 2026 announced November 11, 2026.

What are the latest OPRX SEC filings?

OptimizeRx Corp (OPRX) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on October 2, 2026.

What is OPRX's SEC CIK number?

OptimizeRx Corp (OPRX)'s SEC Central Index Key (CIK) is 1448431. EDGAR lists every OPRX filing under that number.

Ask anything about OPRX

The research agent reads OPRX's filings, financials, insider trades and 13F holders, then answers with sources.